# Massachusetts Court Advances Zimmer Biomet Lawsuit

A federal judge in Massachusetts partially denied Zimmer Biomet Holdings Inc.’s motion for summary judgment in a False Claims Act case alleging that commissions paid to independent sales representatives were intended to induce referrals in violation of the Anti-Kickback Statute, leading to claims submitted to the government. The ruling allows the allegations to proceed but does not establish liability. For federal healthcare procurement professionals and suppliers, the case highlights potential False Claims Act exposure connected to sales-compensation practices and claims submitted for government-funded care.

- Federal healthcare suppliers should assess whether commission structures and referral-related practices could create Anti-Kickback Statute or False Claims Act risk.
- Procurement and compliance teams reviewing supplier relationships should distinguish allegations from established findings; the court’s ruling did not determine that Zimmer Biomet is liable.
- Government contractors should account for the potential impact of sales-practice allegations on claims-submission risk and supplier oversight.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** October 22, 2026

### Government Entities
- U.S. District Court for the District of Massachusetts (D. Mass.)

### Vendors
- Zimmer Biomet Holdings Inc. (False Claims Act defendant)